Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy

被引:25
作者
Juhlin, Kristina [1 ]
Ye, Xiaofei [2 ,3 ]
Star, Kristina [1 ,4 ]
Noren, G. Niklas [1 ,3 ]
机构
[1] WHO Collaborating Ctr Int Drug Monitoring, Uppsala Monitoring Ctr, SE-75140 Uppsala, Sweden
[2] Second Mil Med Univ, Dept Hlth Stat, Shanghai, Peoples R China
[3] Stockholm Univ, Dept Math, S-10691 Stockholm, Sweden
[4] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden
关键词
adverse drug reactions; disproportionality analysis; outliers; masking; statistical shrinkage; competition bias; pharmacoepidemiology; QUANTITATIVE SIGNAL-DETECTION; COMPUTERIZED SYSTEM; COMPETITION BIAS; REPORTING SYSTEM; SAFETY; DISPROPORTIONALITY; PHARMACOVIGILANCE; GENERATION; DATABASES; MASKING;
D O I
10.1002/pds.3474
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeThis study aimed to develop an algorithm for uncovering associations masked by extreme reporting rates, characterize the occurrence of masking by influential outliers in two spontaneous reporting databases and evaluate the impact of outlier removal on disproportionality analysis. MethodsWe propose an algorithm that identifies influential outliers and carries out parallel analysis after their omission. It considers masking of drugs as well as of adverse drug reactions (ADRs), uses a direct measure of the masking effect and makes no assumptions regarding the number of outliers per drug or ADR. The occurrence of masking is characterized in the WHO Global Individual Case Safety Report database, VigiBase and a regional collection of reports from Shanghai, China. ResultsFor WHO-ART critical terms such as myocardial infarction, rhabdomyolysis and hypoglycaemia outlier removal led to a 25-50% increase in the number of Statistics of Disproportionate Reporting (SDR) and gains in time to detection of 1-2years, while keeping the rate of spurious SDRs from the parallel analysis at 1%. Twenty-three per cent of VigiBase and 18% of Shanghai SRS reports listed an influential outlier. Twenty-seven per cent of the ADRs and 5% of the drugs in VigiBase, and 2% of the ADRs and 3% of the drugs in Shanghai SRS were involved in an outlier. The overall increase in the number of SDRs for both datasets was 3%. ConclusionMasking by outliers has substantial impact on specific ADRs including, in VigiBase, rhabdomyolysis, myocardial infarction and hypoglycaemia. It is a local phenomenon involving a fair number of reports but yielding a limited number of additional SDRs. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:1119 / 1129
页数:11
相关论文
共 23 条
[1]   Perspectives on the use of data mining in pharmacovigilance [J].
Almenoff, J ;
Tonning, JM ;
Gould, AL ;
Szarfman, A ;
Hauben, M ;
Ouellet-Hellstrom, R ;
Ball, R ;
Hornbuckle, K ;
Walsh, L ;
Yee, C ;
Sacks, ST ;
Yuen, N ;
Patadia, V ;
Blum, M ;
Johnston, M ;
Gerrits, C ;
Seifert, H ;
LaCroix, K .
DRUG SAFETY, 2005, 28 (11) :981-1007
[2]  
[Anonymous], 2013, Summary of Product Characteristics: trasylol® (aprotinin)
[3]   The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database [J].
Bate, A. ;
Lindquist, M. ;
Edwards, I. R. .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (02) :127-140
[4]   Quantitative signal detection using spontaneous ADR reporting [J].
Bate, A. ;
Evans, S. J. W. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (06) :427-436
[5]   Logistic Regression in Signal Detection: Another Piece Added to the Puzzle [J].
Caster, O. ;
Noren, G. N. ;
Madigan, D. ;
Bate, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) :312-312
[6]   Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database [J].
Caster O. ;
Norén G.N. ;
Madigan D. ;
Bate A. .
Statistical Analysis and Data Mining, 2010, 3 (04) :197-208
[7]  
CIOMS VIII Working Group, 2010, PRACT ASP SIGN DET P
[8]  
DRUGDEX&REG
[9]  
System, MICR 2 0
[10]   Use of measures of disproportionality in pharmacovigilance - Three Dutch examples [J].
Egberts, ACG ;
Meyboom, RHB ;
van Puijenbroek, EP .
DRUG SAFETY, 2002, 25 (06) :453-458